Quote Date: Nov 12, 7:44PM EST

Data delayed 15 minutes Currency in USD

Company Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Exclusive Featured Data Points For ACADIA Pharmaceuticals Inc.

Revenue $208$125$17$0--
Cost of Revenue Expense $12$9$3$0--
Gross Profit $196$116$14$0--
Selling, General & Administrative Expense $263$259$188$91--
Operating Income -$249-$292-$273-$165--
Interest Expense $0$0$0$0--
Pretax Income -$246-$288-$270-$164--
Provision Tax Income $1$0$0$0--
Net Income -$249-$289-$271-$164--
EPS Fully Diluted -$2-$2-$2-$2-$1
EBITDA -$246-$290-$271-$164--
Cash & Cash Equivalents $64$69$164$102--
Short Term Receivables $20$17$6$0--
Inventories $4$5$4$0--
Total Cash $0$0$0$0--
Current Assets $254$373$548$219--
Total Assets $266$385$561$222--
Short Term Debt $0$0$0$0--
Accounts Payable $3$9$4$2--
Total Current Liabilities $42$49$43$22--
Long Term Debt $0$0$0$0--
Deferred Tax Liabilities $0$0$0$0--
Total Liabilities $43$49$43$22--
Total Stock Holders Equity $223$335$518$200--
Total Equity $223$335$518$200--
Operating Cash Flow $0$0$0$0--
Investing Cash Flow $99$92-$262$148--
Dividends Paid $0$0$0$0--
Financing Cash Flow $11$31$534$15--
Free Cash Flow -$160-$219-$220-$124--

Unique Data Points

Nuplazid Revenue $208$125$17----